mitoxantrone has been researched along with Myelodysplastic Syndromes in 39 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since leukemic cells primed by exposure to fludarabine exhibit enhanced accumulation of cytarabine triphosphate (the cytotoxic nucleotide of cytarabine), especially with continuous cytarabine (AraC) infusion, a phase II trial was designed to explore the feasibility and efficacy of a combination chemotherapy associating fludarabine, mitoxantrone (MXN), and high-dose cytarabine (continuous infusion) for high-risk P glycoprotein (PGP)-negative myelodysplastic syndromes (MDS) (FAM protocol)." | 9.11 | A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes. ( Debotton, S; Deconinck, E; Dreyfus, F; Ducastelle, S; Fenaux, P; Fruchart, C; Gratecos, N; Ifrah, N; Prébet, T; Stamatoullas, A; Wattel, E, 2004) |
| " In a chemoimmunotherapy trial conducted between 1997 and 2003 in patients with stage IV indolent lymphoma, 202 patients were treated and 8 have developed MDS between 1 and 5 years after therapy, including 4 who received only fludarabine, mitoxantrone, and dexamethasone (FND) for 6 to 8 courses, with or without rituximab, followed by interferon alpha (IFN-alpha)." | 9.11 | Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. ( Ayala, A; Estey, E; Glassman, A; Hagemeister, FB; Hayes, K; Maddox, AM; McLaughlin, P; Preti, HA; Romaguera, J; Samaniego, F, 2005) |
| "A prospective, randomized, double-blind placebo-controlled trial was designed to evaluate the impact of granulocyte/macrophage-colony-stimulating factor (GM-CSF) on the efficacy of sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy (S-HAM) in adult patients with high-risk myelodysplastic syndromes (MDS)." | 9.09 | Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes. ( Aul, C; Balleisen, L; Bennett, J; Büchner, T; Fonatsch, C; Haase, D; Heinecke, A; Hiddemann, W; Hinrichs, HF; Koch, P; Rowe, JM; Verbeek, W; Wörmann, B, 1999) |
| "Fifty-nine patients who received mitoxantrone as part of adjuvant chemotherapy for breast cancer between 1986 and 1992 were studied to determine the incidence of t-AML and t-MDS." | 9.08 | Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin. ( Cremin, P; Daly, PA; Flattery, M; McCann, SR, 1996) |
| "This large case-control study demonstrates that the risk of AML/MDS is much higher with mitoxantrone-based chemotherapy than with anthracyclines-based chemotherapy in a population of women recently treated for breast cancer." | 7.74 | Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. ( Clisant, S; Cutuli, B; de Vathaire, F; Delaloge, S; Fenaux, P; Hill, C; Le Deley, MC; Linassier, C; Shamsaldin, A; Suzan, F, 2007) |
| "Fludarabine is an effective treatment for follicular lymphoma (FL), but exposure to it negatively impacts stem cell mobilization and may increase the risk of subsequent myelodysplastic syndrome and acute myelogenous leukemia (t-MDS/AML)." | 5.16 | Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. ( Andresen, S; Bolwell, B; Copelan, E; Dean, R; Kalaycio, M; Pohlman, B; Rybicki, L; Sobecks, R; Sweetenham, J; Waterman, J, 2012) |
| "Since leukemic cells primed by exposure to fludarabine exhibit enhanced accumulation of cytarabine triphosphate (the cytotoxic nucleotide of cytarabine), especially with continuous cytarabine (AraC) infusion, a phase II trial was designed to explore the feasibility and efficacy of a combination chemotherapy associating fludarabine, mitoxantrone (MXN), and high-dose cytarabine (continuous infusion) for high-risk P glycoprotein (PGP)-negative myelodysplastic syndromes (MDS) (FAM protocol)." | 5.11 | A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes. ( Debotton, S; Deconinck, E; Dreyfus, F; Ducastelle, S; Fenaux, P; Fruchart, C; Gratecos, N; Ifrah, N; Prébet, T; Stamatoullas, A; Wattel, E, 2004) |
| " In a chemoimmunotherapy trial conducted between 1997 and 2003 in patients with stage IV indolent lymphoma, 202 patients were treated and 8 have developed MDS between 1 and 5 years after therapy, including 4 who received only fludarabine, mitoxantrone, and dexamethasone (FND) for 6 to 8 courses, with or without rituximab, followed by interferon alpha (IFN-alpha)." | 5.11 | Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. ( Ayala, A; Estey, E; Glassman, A; Hagemeister, FB; Hayes, K; Maddox, AM; McLaughlin, P; Preti, HA; Romaguera, J; Samaniego, F, 2005) |
| "A prospective, randomized, double-blind placebo-controlled trial was designed to evaluate the impact of granulocyte/macrophage-colony-stimulating factor (GM-CSF) on the efficacy of sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy (S-HAM) in adult patients with high-risk myelodysplastic syndromes (MDS)." | 5.09 | Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes. ( Aul, C; Balleisen, L; Bennett, J; Büchner, T; Fonatsch, C; Haase, D; Heinecke, A; Hiddemann, W; Hinrichs, HF; Koch, P; Rowe, JM; Verbeek, W; Wörmann, B, 1999) |
| "Fifty-nine patients who received mitoxantrone as part of adjuvant chemotherapy for breast cancer between 1986 and 1992 were studied to determine the incidence of t-AML and t-MDS." | 5.08 | Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin. ( Cremin, P; Daly, PA; Flattery, M; McCann, SR, 1996) |
| "Thirty-one adult patients with high-risk myelodysplastic syndromes (MDS) were enrolled in a prospective randomized double-blind placebo-controlled trial evaluating the efficacy of sequential high-dose Ara C/mitoxantrone chemotherapy with or without GM-CSF." | 5.08 | S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes. ( Aul, C; Balleisen, L; Bennett, J; Büchner, T; Hiddemann, W; Hinrichs, H; Koch, P; Rowe, JM; Verbeek, W; Wörmann, B, 1997) |
| "This large case-control study demonstrates that the risk of AML/MDS is much higher with mitoxantrone-based chemotherapy than with anthracyclines-based chemotherapy in a population of women recently treated for breast cancer." | 3.74 | Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. ( Clisant, S; Cutuli, B; de Vathaire, F; Delaloge, S; Fenaux, P; Hill, C; Le Deley, MC; Linassier, C; Shamsaldin, A; Suzan, F, 2007) |
| " We report the case history of a patient with myelodyspasia occurring after neoadjuvant methotrexate, mitoxantrone and mitomycin C (triple M) chemotherapy with subsequent radiotherapy for locally advanced breast cancer." | 3.70 | Myelodysplastic syndrome as a complication of neo-adjuvant triple M chemotherapy and radiotherapy. ( Lowdell, CP; Partridge, SE, 1999) |
| "Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2." | 3.70 | Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. ( Ashley, S; Kuan, A; Kulkarni, S; Mehta, J; Mitchell, P; Powles, R; Powles, T; Saso, R; Swansbury, GJ; Treleaven, J, 2000) |
| "To evaluate the clinical relevance of multidrug resistance (MDR) phenotype, the intracellular daunorubicin accumulation (IDA) and P-glycoprotein (P-gp) expression were investigated in 87 adult patients with acute leukemia: 69 patients with de novo acute myeloid leukemia (AML), 10 with AML at relapse, and eight with secondary leukemia to myelodysplastic syndromes (MDS-AML)." | 3.69 | Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. ( Feldmann, L; Guerci, A; Guerci, O; Marchal, S; Merlin, JL; Missoum, N; Rose, C; Witz, F, 1995) |
| "Maintenance treatment also reduced minimal residual disease (detected by WT1 and CBFβ-MYH11) in five of eight evaluable patients." | 2.79 | Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents. ( Audisio, E; Boccadoro, M; Bruno, B; Crisà, E; Ferrero, D; Festuccia, M; Frairia, C; Gatti, T; Giai, V; Marmont, F; Passera, R; Riera, L, 2014) |
| "Azathioprine sodium use was observed more frequently in cases (odds ratio [OR], 7." | 1.46 | Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. ( Al-Kali, A; Castro, J; Dueck, A; Ertz-Archambault, N; Finn, L; Foran, J; Gauthier, S; Kelemen, K; Kosiorek, H; Marino, R; Mesa, RA; Palmer, J; Sproat, LZ; Taylor, GE; Tibes, R, 2017) |
| "For patients with acute myeloid leukemia from antecedent myelodysplastic syndrome particularly after azanucleoside treatment failure, outcome is poor." | 1.40 | Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. ( Al Ali, NH; Bello, CM; Duong, VH; Fernandez, HF; Jaglal, MV; Komrokji, RS; Lancet, JE; List, AF; Padron, E, 2014) |
| "Treatment of acute promyelocytic leukemia (APL) with a combination of anthracycline-based chemotherapy and all-trans retinoic acid (ATRA) leads to very high rates of complete remission and survival." | 1.35 | Translocation (2;11)(q37;q23) in therapy-related myelodysplastic syndrome after treatment for acute promyelocytic leukemia. ( Mellink, CH; Snijder, S; van der Lelie, H, 2008) |
| "From 1998 to 2001, 5 consecutive cases of AML/TMDS entered our hospital and achieved complete remission (CR) with continuous drip infusion of low-dose etoposide and low-dose Ara-C combined with mitoxantrone (MEtA regimen)." | 1.32 | [Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)]. ( Furukawa, Y; Kitani, T; Shibano, M; Tsukaguchi, M, 2004) |
| "We report on a patient with Fanconi's anemia (FA) who developed a myelodysplastic syndrome (RAEB-T) with complex karyotypic abnormalities (trp 1q23q42, monosomy 20, trisomy 13) at the age of 28." | 1.30 | Induction of a hematological and cytogenetic remission in a patient with a myelodysplastic syndrome secondary to Fanconi's anemia employing the S-HAM regimen. ( Haase, D; Hiddemann, W; Schoch, C; Verbeek, W; Wörmann, B, 1997) |
| "AMH resembling acute megakaryoblastic leukemia may be seen transiently after treatment of AML." | 1.28 | Dysmegakaryopoiesis resembling acute megakaryoblastic leukemia in treated acute myeloid leukemia. ( Farhi, DC; Rosenthal, NS, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (38.46) | 18.2507 |
| 2000's | 17 (43.59) | 29.6817 |
| 2010's | 7 (17.95) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rashidi, A | 1 |
| Ali, AM | 1 |
| Vij, KR | 1 |
| Shanley, R | 1 |
| Romee, R | 1 |
| Cooley, SA | 1 |
| Westervelt, P | 1 |
| DiPersio, JF | 1 |
| Miller, JS | 1 |
| Weisdorf, DJ | 1 |
| Ustun, C | 1 |
| Boddu, PC | 1 |
| Zeidan, AM | 1 |
| Jaglal, MV | 1 |
| Duong, VH | 1 |
| Bello, CM | 1 |
| Al Ali, NH | 1 |
| Padron, E | 1 |
| Fernandez, HF | 1 |
| List, AF | 1 |
| Lancet, JE | 1 |
| Komrokji, RS | 1 |
| Robak, T | 1 |
| Wierzbowska, A | 1 |
| Ferrero, D | 1 |
| Crisà, E | 1 |
| Marmont, F | 1 |
| Audisio, E | 1 |
| Frairia, C | 1 |
| Giai, V | 1 |
| Gatti, T | 1 |
| Festuccia, M | 1 |
| Bruno, B | 1 |
| Riera, L | 1 |
| Passera, R | 1 |
| Boccadoro, M | 1 |
| Ertz-Archambault, N | 1 |
| Kosiorek, H | 1 |
| Taylor, GE | 1 |
| Kelemen, K | 1 |
| Dueck, A | 1 |
| Castro, J | 1 |
| Marino, R | 1 |
| Gauthier, S | 1 |
| Finn, L | 1 |
| Sproat, LZ | 1 |
| Palmer, J | 1 |
| Mesa, RA | 1 |
| Al-Kali, A | 1 |
| Foran, J | 1 |
| Tibes, R | 1 |
| Waterman, J | 1 |
| Rybicki, L | 1 |
| Bolwell, B | 1 |
| Copelan, E | 1 |
| Pohlman, B | 1 |
| Sweetenham, J | 1 |
| Dean, R | 1 |
| Sobecks, R | 1 |
| Andresen, S | 1 |
| Kalaycio, M | 1 |
| Kobbe, G | 2 |
| Germing, U | 2 |
| Aivado, M | 2 |
| Zohren, F | 1 |
| Schubert, D | 1 |
| Strupp, C | 1 |
| Pape, H | 1 |
| Tenderich, G | 1 |
| Körfer, R | 1 |
| Storb, R | 1 |
| Haas, R | 2 |
| Schneider, P | 1 |
| Greenberg, PL | 1 |
| Lee, SJ | 1 |
| Advani, R | 1 |
| Tallman, MS | 1 |
| Sikic, BI | 1 |
| Letendre, L | 1 |
| Dugan, K | 1 |
| Lum, B | 1 |
| Chin, DL | 1 |
| Dewald, G | 1 |
| Paietta, E | 2 |
| Bennett, JM | 2 |
| Rowe, JM | 4 |
| Bolaños-Meade, J | 1 |
| Guo, C | 1 |
| Gojo, I | 1 |
| Karp, JE | 1 |
| Prébet, T | 1 |
| Ducastelle, S | 1 |
| Debotton, S | 1 |
| Stamatoullas, A | 1 |
| Deconinck, E | 1 |
| Fruchart, C | 1 |
| Gratecos, N | 4 |
| Ifrah, N | 3 |
| Dreyfus, F | 4 |
| Fenaux, P | 5 |
| Wattel, E | 4 |
| Tsukaguchi, M | 1 |
| Furukawa, Y | 1 |
| Shibano, M | 1 |
| Kitani, T | 1 |
| McLaughlin, P | 1 |
| Estey, E | 1 |
| Glassman, A | 1 |
| Romaguera, J | 1 |
| Samaniego, F | 1 |
| Ayala, A | 1 |
| Hayes, K | 1 |
| Maddox, AM | 1 |
| Preti, HA | 1 |
| Hagemeister, FB | 1 |
| Au, WY | 1 |
| Chan, LC | 1 |
| Liang, R | 1 |
| Kwong, YL | 1 |
| Büchner, T | 3 |
| Berdel, WE | 2 |
| Schoch, C | 2 |
| Haferlach, T | 1 |
| Serve, HL | 1 |
| Kienast, J | 1 |
| Schnittger, S | 1 |
| Kern, W | 1 |
| Tchinda, J | 1 |
| Reichle, A | 1 |
| Lengfelder, E | 1 |
| Staib, P | 1 |
| Ludwig, WD | 1 |
| Aul, C | 5 |
| Eimermacher, H | 1 |
| Balleisen, L | 3 |
| Sauerland, MC | 1 |
| Heinecke, A | 2 |
| Wörmann, B | 4 |
| Hiddemann, W | 5 |
| Le Deley, MC | 1 |
| Suzan, F | 1 |
| Cutuli, B | 1 |
| Delaloge, S | 1 |
| Shamsaldin, A | 1 |
| Linassier, C | 1 |
| Clisant, S | 1 |
| de Vathaire, F | 1 |
| Hill, C | 1 |
| Snijder, S | 1 |
| Mellink, CH | 1 |
| van der Lelie, H | 1 |
| Guerci, A | 4 |
| Merlin, JL | 1 |
| Missoum, N | 1 |
| Feldmann, L | 1 |
| Marchal, S | 1 |
| Witz, F | 1 |
| Rose, C | 1 |
| Guerci, O | 1 |
| Knauf, WU | 2 |
| Ho, AD | 2 |
| Kreuser, ED | 1 |
| Thiel, E | 1 |
| Hiçsönmez, G | 1 |
| Tuncer, AM | 1 |
| Sayli, T | 1 |
| Güler, E | 1 |
| Cetin, M | 1 |
| Ozbek, N | 1 |
| Mufti, GJ | 1 |
| Cremin, P | 1 |
| Flattery, M | 1 |
| McCann, SR | 1 |
| Daly, PA | 1 |
| Verbeek, W | 3 |
| Koch, P | 2 |
| Hinrichs, H | 1 |
| Bennett, J | 2 |
| Haase, D | 2 |
| Dissing, M | 1 |
| Le Beau, MM | 1 |
| Pedersen-Bjergaard, J | 1 |
| Nagler, A | 1 |
| Soni, S | 1 |
| Samuel, S | 1 |
| Or, R | 1 |
| Solary, E | 3 |
| Hecquet, B | 2 |
| Caillot, D | 2 |
| Brion, A | 3 |
| Mahé, B | 1 |
| Milpied, N | 2 |
| Janvier, M | 3 |
| Rochant, H | 3 |
| Cordonnier, C | 2 |
| Buzyn, A | 1 |
| Hoang-Ngoc, L | 3 |
| Stoppa, AM | 2 |
| Sadoun, A | 2 |
| Stamatoulas, A | 1 |
| Tilly, H | 2 |
| Brice, P | 3 |
| Maloisel, F | 2 |
| Lioure, B | 2 |
| Desablens, B | 2 |
| Leleu, X | 1 |
| Jouet, JP | 1 |
| Casassus, P | 1 |
| Lepelley, P | 1 |
| Hinrichs, HF | 1 |
| Fonatsch, C | 1 |
| Partridge, SE | 1 |
| Lowdell, CP | 1 |
| Veil, A | 1 |
| Pignon, B | 1 |
| Abgrall, JP | 1 |
| Leporrier, M | 1 |
| Latagliata, R | 1 |
| Breccia, M | 1 |
| Pulsoni, A | 1 |
| Aloe Spiriti, MA | 1 |
| D'Elia, GM | 1 |
| Spadea, A | 1 |
| Montefusco, E | 1 |
| Luzi, G | 1 |
| Betrò, P | 1 |
| Petti, MC | 1 |
| Saso, R | 1 |
| Kulkarni, S | 1 |
| Mitchell, P | 1 |
| Treleaven, J | 1 |
| Swansbury, GJ | 1 |
| Mehta, J | 1 |
| Powles, R | 1 |
| Ashley, S | 1 |
| Kuan, A | 1 |
| Powles, T | 1 |
| Rong, A | 1 |
| Gattermann, N | 1 |
| Rieth, C | 1 |
| Seiter, K | 1 |
| Feldman, EJ | 1 |
| Sreekantaiah, C | 1 |
| Pozzuoli, M | 1 |
| Weisberger, J | 1 |
| Liu, D | 1 |
| Papageorgio, C | 1 |
| Weiss, M | 1 |
| Kancherla, R | 1 |
| Ahmed, T | 1 |
| Young, MS | 1 |
| Liesveld, JL | 1 |
| Miller, KB | 1 |
| Lazarus, HM | 1 |
| Marsh, RD | 1 |
| Friedenberg, WR | 1 |
| Saba, HT | 1 |
| Hayes, FA | 1 |
| Dewald, GW | 1 |
| Wulf, GG | 1 |
| Wang, RY | 1 |
| Kuehnle, I | 1 |
| Weidner, D | 1 |
| Marini, F | 1 |
| Brenner, MK | 1 |
| Andreeff, M | 1 |
| Goodell, MA | 1 |
| de Witte, T | 1 |
| Suciu, S | 1 |
| Verhoef, G | 1 |
| Labar, B | 1 |
| Archimbaud, E | 1 |
| Selleslag, D | 1 |
| Ferrant, A | 1 |
| Wijermans, P | 1 |
| Mandelli, F | 1 |
| Amadori, S | 1 |
| Jehn, U | 1 |
| Muus, P | 1 |
| Boogaerts, M | 1 |
| Zittoun, R | 1 |
| Gratwohl, A | 1 |
| Zwierzina, H | 1 |
| Hagemeijer, A | 1 |
| Willemze, R | 1 |
| Körbling, M | 1 |
| Hunstein, W | 1 |
| Rosenthal, NS | 1 |
| Farhi, DC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia[NCT01822015] | Early Phase 1 | 55 participants (Actual) | Interventional | 2013-03-15 | Completed | ||
| Intrabone Infusion of Cord Blood Hemopoietic Stem Cells in Adult Patients With High Risk Haematological Malignancies.[NCT00886522] | Phase 2 | 23 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With RAEB-1 AND RAEB-2 Myelodysplastic Syndrome (MDS) and AML With Trisomy 8[NCT00533416] | Phase 1 | 14 participants (Actual) | Interventional | 2007-09-14 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for mitoxantrone and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state.
Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cladribine; Co | 2017 |
Myeloid disorders after autoimmune disease.
Topics: Arthritis, Rheumatoid; Cyclophosphamide; Genetic Predisposition to Disease; Humans; Immunosuppressiv | 2019 |
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chrom | 2001 |
16 trials available for mitoxantrone and Myelodysplastic Syndromes
20 other studies available for mitoxantrone and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Case-Co | 2014 |
Cladribine in the treatment of acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cladribine; Cytarabine; Female; Filgras | 2014 |
Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Autoimmune Diseases; Azathioprine; Case-Control Stud | 2017 |
Treatment of secondary myelodysplastic syndrome after heart transplantation with chemotherapy and nonmyeloablative stem-cell transplantation.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2002 |
[Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Lineage; Cytarabine; Disease-Free Surviv | 2004 |
Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans | 2006 |
Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Breast Neoplas | 2007 |
Translocation (2;11)(q37;q23) in therapy-related myelodysplastic syndrome after treatment for acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Chromosomes, Human, Pair 11; Chromo | 2008 |
Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemot | 1995 |
Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Leukemia, My | 1994 |
High-dose methylprednisolone, low-dose cytosine arabinoside, and mitoxantrone in children with myelodysplastic syndromes.
Topics: Adolescent; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Drug Administrati | 1995 |
Induction of a hematological and cytogenetic remission in a patient with a myelodysplastic syndrome secondary to Fanconi's anemia employing the S-HAM regimen.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Fanconi A | 1997 |
Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chromosome Inv | 1998 |
Myelodysplastic syndrome as a complication of neo-adjuvant triple M chemotherapy and radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Methotrexate; Midd | 1999 |
Acute myeloblastic leukemia secondary to myelodysplasia (MDS-AML): a comparison of remission induction with three drugs versus standard two-drugs induction.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; | 2000 |
Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2000 |
Long-term remission after intensive chemotherapy in advanced myelodysplastic syndromes is generally associated with restoration of polyclonal haemopoiesis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubi | 2000 |
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antibiotics, Antineoplastic; Ant | 2001 |
Combination therapy with mitoxantrone and etoposide in adult acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Evaluat | 1990 |
Dysmegakaryopoiesis resembling acute megakaryoblastic leukemia in treated acute myeloid leukemia.
Topics: Acute Disease; Antigens, CD; Bone Marrow; Cytarabine; Daunorubicin; Diagnosis, Differential; Doxorub | 1991 |